1-(4-Benzhydryl-piperazin-1-yl)-3-benzoimidazol-1-yl-propan-2-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-Benzhydryl-piperazin-1-yl)-3-benzoimidazol-1-yl-propan-2-ol
• 英文别名: 1-(4-Benzhydrylpiperazin-1-yl)-3-(benzimidazol-1-yl)propan-2-ol
• 化学式: C₂₇H₃₀N₄O
• 分子量: 426.561
• InChiKey: VJQGEEWWQQUPMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  二苯甲基哌嗪 在 sodium hydroxide 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 二甲基亚砜 为溶剂， 反应 34.0h， 生成 1-(4-Benzhydryl-piperazin-1-yl)-3-benzoimidazol-1-yl-propan-2-ol
  参考文献：
  名称：

  Synthesis and Structure-Activity Relationships of 6-Heterocyclic-Substituted Purines as Inactivation Modifiers of Cardiac Sodium Channels

  摘要：

  Purine-based analogs of SDZ 211-500 (5) were prepared and evaluated as inactivation modifiers of guinea pig or human cardiac sodium (Na) channels expressed in Xenopus oocytes. Substances which remove or slow the Na channel inactivation process in cardiac tissue are anticipated to prolong the effective refractory period and increase inotropy and thus have potential utility as antiarrhythmic agents. Heterocyclic substitution at the 6-position of the purine ring resulted in compounds with increased Na activity and potency, with 5-membered heterocycles being optimal. Only minor modifications to the benzhydrylpiperazine side chain were tolerated. Selected compounds which delayed the inactivation of Na channels were found to increase refractoriness and contractility in a rabbit Langendorff heart model, consistent with the cellular mechanism. Activity in both the oocyte and rabbit heart assays was specific to the S enantiomers. Preliminary in vivo activity has been demonstrated following intravenous infusion. The most promising compound on the basis of in vitro data is the formylpyrrole (S)-74, which is 25-fold more potent than DPI 201-106 (1) in the human heart Na channel assay.

  DOI：

  10.1021/jm00014a011

文献信息

• Dopamine D4 ligands for the treatment of novelty-seeking disorders
  申请人：——

  公开号：US20020049209A1

  公开（公告）日：2002-04-25

  The present invention provides a method of treating or preventing a novelty-seeking disorder such as pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction. using a compound which is a dopamine D4 receptor ligand, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗或预防新奇寻求障碍，如病理性赌博、注意力缺陷多动障碍、物质成瘾、药物成瘾、酒精成瘾和性成瘾的方法。所使用的化合物是多巴胺D4受体配体或其药学上可接受的盐。
• Dopamine D4 Ligands for the treatment of novelty-seeking disorders
  申请人：Pfizer Products Inc.

  公开号：EP1177792A2

  公开（公告）日：2002-02-06

  The use of a dopamine D4 receptor ligand in the manufacture of a medicament for the treatment or prevention of a novelty-seeking disorder, particularly pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction.

  使用多巴胺 D4 受体配体制造用于治疗或预防寻求新奇障碍的药物，特别是病态赌博、多动障碍性注意力缺陷症、药物成瘾、吸毒成瘾、酗酒成瘾和性成瘾。
• BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY
  申请人：PFIZER INC.

  公开号：EP0775118A1

  公开（公告）日：1997-05-28
• US5889010A
  申请人：——

  公开号：US5889010A

  公开（公告）日：1999-03-30
• US6548502B2
  申请人：——

  公开号：US6548502B2

  公开（公告）日：2003-04-15